GE HEALTHCARE TECHNOLOGIES INC. (GEHC) Spending and interest coverage
- R&D / revenue · 12 months: Value 6.01%; Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value 0.68%; Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 6.01% | Research and development expense / revenue. Period ending 2026-03-31. $1.26B ÷ $20.98B × 100 ≈ 6.01% |
| Stock-based compensation / revenue · 12 months | 0.68% | Share-based compensation / revenue. Period ending 2026-03-31. $143.00M ÷ $20.98B × 100 ≈ 0.68% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.26B USD | Research and Development Expense |
| Revenue | 20.98B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 143.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 2.65B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $1.26B | $20.98B | $143.00M | $2.65B | (m) | 6.01% | 0.68% | (m) | (m) |
| 2025-12-31 | $1.26B | $20.63B | $130.00M | $2.76B | (m) | 6.11% | 0.63% | (m) | (m) |
| 2025-09-30 | $1.28B | $20.25B | $127.00M | $2.74B | (m) | 6.33% | 0.63% | (m) | (m) |
| 2025-06-30 | $1.31B | $19.97B | $111.00M | $2.76B | (m) | 6.54% | 0.56% | (m) | (m) |
| 2025-03-31 | $1.33B | $19.80B | $113.00M | $2.71B | (m) | 6.72% | 0.57% | (m) | (m) |
| 2024-12-31 | $1.31B | $19.67B | $125.00M | $2.63B | (m) | 6.66% | 0.64% | (m) | (m) |
| 2024-09-30 | $1.28B | $19.56B | $125.00M | $2.51B | (m) | 6.55% | 0.64% | (m) | (m) |
| 2024-06-30 | $1.29B | $19.52B | $132.00M | $2.45B | (m) | 6.60% | 0.68% | (m) | (m) |
| 2024-03-31 | $1.26B | $19.50B | $124.00M | $2.42B | (m) | 6.46% | 0.64% | (m) | (m) |
| 2023-12-31 | $1.21B | $19.55B | $114.00M | $2.44B | (m) | 6.16% | 0.58% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.03B | $18.34B | $67.00M | $2.52B | (m) | 5.59% | 0.37% | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $816.00M | $17.59B | $76.00M | $2.79B | (m) | 4.64% | 0.43% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.